ArticleERJ open research2026

Upfront combination therapy with nintedanib and anti-inflammatory agents for progressive pulmonary fibrosis: a multicentre, single-arm phase 2 study (TOP-ILD).

Kazuya Tsubouchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.